Bio-Rad stock looks undervalued, boosted by its Sartorius stake, but headwinds and volatile guidance cap upside. Click here ...

Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The third quarter was a strong one for the fund ...

Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the ...

Throughout the last three months, 5 analysts have evaluated Bio-Rad Laboratories (NYSE:BIO), offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

Framing Bio-Rad Laboratories after recent performance Bio-Rad Laboratories (BIO) has been under pressure recently, with the ...

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Bio-Rad Laboratories as such a stock due to the following factors: BIO has an average ...

This article first appeared on GuruFocus. Bio-Rad Laboratories Inc (NYSE:BIO) is set to release its Q3 2025 earnings on Oct 29, 2025. The consensus estimate for Q3 2025 revenue is $651.30 million, and ...

Bio-Rad Laboratories, Inc. is an American multinational manufacturer and distributor of life science research and clinical diagnostic products. The company was founded in 1952 in Berkeley, California, ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, and Element Biosciences, Inc., developer of a new DNA sequencing platform ...

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24 ...